Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 8/2012

01-11-2012 | Original Research

Neurological Function, Information–Motivation–Behavioral Skills Factors, and Risk Behaviors Among HIV-Positive Alcohol Users

Authors: Robert M. Malow, Jessy G. Dévieux, Judith A. Stein, Rhonda Rosenberg, Brenda G. Lerner, Jennifer Attonito, Karina Villalba

Published in: AIDS and Behavior | Issue 8/2012

Login to get access

Abstract

The purpose of this study was to examine neurological impairment in combination with information–motivation–behavioral skills (IMB) variables. The study tests the role of IMB variables as mediators of antecedent variables of demographics, life stress, social support, and neurological impairment with outcome measures of HIV preventive and risk behaviors in a sample of HIV-positive, alcohol-using adults (n = 250) with a history of alcohol abuse/dependence. Neurological impairment was measured with the Color Trails Test (CTT). Average performance on the CTT by the sample was substantially worse than established norms. In a directional latent variable model, neurological impairment directly predicted lower transmission knowledge scores and poorer performance on an observational condom skills assessment. Greater neurological impairment was significantly associated with greater age. Future interventions geared toward HIV+ adults who use alcohol should take into consideration HIV-related and age-related neurological functioning which may impede the facilitation of safe sex behaviors.
Literature
1.
2.
Fisher JD, Fisher WA, Williams SS, Malloy TE. Empirical tests of an information-motivation-behavioral skills model of AIDS-preventive behavior with gay men and heterosexual university students. Health Psychol. 1994;13:238–50.PubMedCrossRef
3.
Malow RM, Stein JA, McMahon RC, Dévieux JG, Rosenberg R, Jean-Gilles M. Effects of a culturally adapted HIV prevention intervention in Haitian youth. J Assoc Nurses AIDS Care. 2009;20(2):110–21.PubMedCrossRef
4.
Kalichman S, Malow R, Devieux J, Stein JA, Piedman F. HIV risk reduction for substance using seriously mentally ill adults: test of the information-motivation-behavior skills (IMB) model. Commun Ment Health J. 2005;41(3):277–89.CrossRef
5.
Kalichman SC, Picciano JF, Roffman RA. Motivation to reduce HIV risk behaviors in the context of the information, motivation and behavioral skills (IMB) model of HIV prevention. J Health Psychol. 2008;13(5):680–9.PubMedCrossRef
6.
Bryan A, Fisher J, Fisher W, Murray D. Understanding condom use among heroin addicts in methadone maintenance using the information–motivation–behavioral skills model. Subs Abuse Misuse. 2000;35(1):451–47.
7.
Kalichman S, Stein J, Malow R, Averhart C, Dévieux J, Jennings T, et al. Predicting protected sexual behaviour using the information–motivation–behaviour skills model among adolescent substance abusers in court-ordered treatment. Psychol Health Med. 2002;7(3):327–39.PubMedCrossRef
8.
Norman LR, Basso M, Kumar A, Malow R. Neuropsychological consequences of HIV and substance abuse: a literature review and implications for treatment and future research. Curr Drug Abuse Rev. 2009;2(2):143–56.PubMedCrossRef
9.
Durvasula R, Norman L, Malow R. Current perspectives on the neuropsychology of HIV. In: Pope C, White R, Malow R, editors. HIV/AIDS: global frontiers in prevention/intervention. New York: Routledge; 2009. p. 177–90.
10.
Antinori A, Arendt G, Becker J, Brew B, Byrd D, Cherner M, et al. Updated research nosology for HIV associated neurocognitive disorders. Neurology. 2007;69:1789–99.PubMedCrossRef
11.
del Palacio M, Álvarez S, Muñoz-Fernández MÁ. HIV-1 infection and neurocognitive impairment in the current era. Rev Med Virol. 2011;85(21):11468–78.
12.
Gandhi NS, Skolasky RL, Peters KB, Moxley RT 4th, Creighton J, Roosa HV, Selnes OA, McArthur J, Sacktor N. A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. J Neurovirol. 2011;17:159–65.PubMedCrossRef
13.
Foley JM, Wright MJ, Gooding AL, Ettenhofer M, Kim M, Choi M, Castellon SA, Sadek J, Heaton RK, van Gorp WG, Marcotte TD, Hinkin CH. Operationalization of the updated diagnostic alogarithm for classifying HIV-related cognitive impairment and dementia. Int Psychogeriatr. 2011;23(5):835–43.CrossRef
14.
Gisslén M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis. 2011;11:356.PubMedCrossRef
15.
Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002;8(2):115–21.PubMedCrossRef
16.
Lopez OL, Smith G, Meltzer CC, Becker JT. Dopamine systems in human immunodeficiency virus-associated dementia. Neuropsychiatry Neuropsychol Behav Neurol. 1999;12(3):184–92.PubMed
17.
Woods S, Moore D, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009;19(2):152–68.PubMedCrossRef
18.
Samet JH, Phillips SJ, Horton NJ, Traphagen ET, Freedberg KA. Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retrovir. 2004;20(2):151–5.PubMedCrossRef
19.
Conigliaro J, Justice AC, Gordon AJ, Bryant K, VACS Alcohol and Behavior Change Research Group. Role of alcohol in determining human immunodeficiency virus (HIV)-relevant outcomes: a conceptual model to guide the implementation of evidence-based interventions into practice. Med Care. 2006;44(8 Supl. 2):S1–S6.
20.
Farinpour R, Martin EM, Seidenberg M, Pitrak DL, Pursell KJ, Mullane KM, Novak RM, Harrow M. Verbal working memory in HIV-seropositive drug users. J Int Neuropsychol Soc. 2000;6:548–55.PubMedCrossRef
21.
Martin EM, Pitrak DL, Weddington W, Rains NA, Nunnally G, Nixon H, Grbesic S, Vassileva J, Bechara A. Cognitive impulsivity and HIV serostatus in substance dependent males. J Int Neuropsychol Soc. 2004;10(7):931–8.PubMedCrossRef
22.
Rothlind JC, Greenfield TM, Bruce AV, Meyerhoff DJ, Flenniken DL, Lindgren JA, Weiner MW. Heavy alcohol consumption in individuals with HIV infection: effects on neuropsychological performance. J Int Neuropsychol Soc. 2005;11(1):70–83.PubMedCrossRef
23.
Centers for Disease Control and Prevention. Establishing a holistic framework to reduce inequities in HIV, viral hepatitis, STDS, and tuberculosis in the United States. Atlanta: Department of Health and Human Services; 2010.
24.
Koopman C, Gore-Felton C, Marouf F, Butler LD, Field N, Gill M, Chen XH, Israelski D, Spiegel D. Relationships of perceived stress to coping, attachment and social support among HIV-positive persons. AIDS Care. 2000;12(5):663–72.PubMedCrossRef
25.
Reif S, Mugavero M, Raper J, Thielman N, Leserman J, Whetten K, Pence BW. Highly stressed: stressful and traumatic experiences among individuals with HIV/AIDS in the Deep South. AIDS Care. 2011;23(2):152–62.PubMedCrossRef
26.
McMahon RC, Penedo FJ, Loewinger L, Jennings TE. Stress, social support and HIV risk among drug dependent men. Am Psychol. 1998;53(8):882–939.
27.
Pence BW, Raper JL, Reif S, Thielman NM, Leserman J, Mugavero MJ. Incident stressful and traumatic life events and human immunodeficiency virus sexual transmission risk behaviors in a longitudinal, multisite cohort study. Psychosom Med. 2010;72(7):720–6.PubMedCrossRef
28.
Miller GE, Cole SW. Social relationships and the progression of human immunodeficiency virus infection: a review of evidence and possible underlying mechanisms. Ann Behav Med. 1998;20(3):181–9.PubMedCrossRef
29.
Adib SM, Joseph JG, Ostrow DG, James SA. Predictors of relapse in sexual practices among homosexual men. AIDS Educ Prev. 1991;3:293–304.PubMed
30.
Kimberly JA, Serovich JM. The role of family and friend social support in reducing risk behaviors among HIV-positive gay men. AIDS Educ Prev. 1999;11(6):465–75.PubMed
31.
St. Lawrence JS, Brasfield TL, Jefferson KW, Allyene E, Shirley A. Social support as a factor in African–American adolescents’ sexual risk behavior. J Adolesc Res. 1994;9(3):292–10.
32.
McMahon RC, Malow RM, Jennings TE. Personality, stress, and social support in HIV risk prediction. AIDS Behav. 2000;4(4):399–410.CrossRef
33.
D’Elia L, Satz P, Uchiyama C, White T. Color Trails Test. Odessa: Psychological Assessment Resources; 1996.
34.
Tombaugh T. Trail making test A and B: normative data stratified by age and education. Archiv Clin Neuropsychol. 2004;19:203–14.CrossRef
35.
Maj M, Satz P, Janssen R, Zaudig M, Starace F, D’Elia L, Sughondhabirom B, Mussa M, Naber D, Ndetei D, et al. WHO neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry. 1994;51(1):51–61.PubMedCrossRef
36.
Bornstein R. Normative data on selected neuropsychological measures from a nonclinical sample. J Clin Psychol. 1985;41(5):651–9.CrossRef
37.
Sarason IG, Johnson JH, Siegel JM. Assessing the impact of life changes: development of the life experiences survey. J Consult Clin Psychol. 1978;46:932–46.PubMedCrossRef
38.
Yuan KH, Bentler PM, Kano Y. On averaging variables in a confirmatory factor analysis model. Behaviormetrika. 1997;24:71–83.CrossRef
39.
40.
Jaworski BC, Carey MP. Development and psychometric evaluation of a self-administered questionnaire to measure knowledge of sexually transmitted diseases. AIDS Behav. 2007;11:557–74.PubMedCrossRef
41.
DeHart DD, Birkimer JC. Trying to practice safer sex: development of the sexual risks scale. J Sex Res. 1997;34:11–25.CrossRef
42.
Brien TM, Thombs DL, Mahoney CA, Wallnau L. Dimensions of self-efficacy among three distinct groups of condom users. J Am Coll Health. 1994;42:167–74.PubMedCrossRef
43.
Brafford LJ, Beck KH. Development and validation of a condom self-efficacy scale for college students. J Am Coll Health. 1991;39:219–25.PubMedCrossRef
44.
Malow R, Dévieux JG, Rosenberg R, Capp L, Schneiderman N. A cognitive-behavioral intervention for HIV+ recovering drug abusers: the 2000–2005 NIDA-funded AIDS prevention center study. Psychol AIDS Exch. 2001;30:23–6.
45.
Sorensen JL, London J, Morales E. Group counseling to prevent AIDS. In: Sorensen J, Wermuth L, Gibson D, Choi K, Guydish J, Batki S, editors. Preventing AIDS in drug users and their sexual partners. New York: Guilford; 1991. p. 99–115.
46.
National Institute on Drug Abuse (NIDA). NIDA risk behavior assessment. Rockville: NIDA; 1991.
47.
Carey MP, Carey KB, Maisto SA, Gordon CM, Weinhardt LS. Assessing sexual risk behaviour with the timeline followback (TLFB) approach: continued development and psychometric evaluation with psychiatric outpatients. Int J STD AIDS. 2001;12:365–75.PubMedCrossRef
48.
Weinhardt LS, Carey MP, Maisto SA, Carey KB, Cohen MM, Wickramasinghe SM. Reliability of the timeline followback sexual behavior interview. Ann Behav Med. 1998;20:25–30.
49.
Weinhardt LS, Otto-Salaj LL, Brondino MJ, Norberg MM, Kalichman S. Sex-related alcohol expectancies predict sexual risk behavior among severely and persistently mentally ill adults. Psychol Addict Behav. 2002;16:64–7.PubMedCrossRef
50.
Bentler PM. EQS structural equations program manual. Encino: Multivariate Software; 2006.
51.
Hu LT, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model. 1999;6:1–55.CrossRef
52.
Chou CP, Bentler PM. Model modification in covariance structure modeling: a comparison among likelihood ratio, Lagrange Multiplier, and Wald tests. Multivar Behav Res. 1990;25:115–36.CrossRef
53.
MacCallum RC. Specification searches in covariance structure modeling. Psychol Bull. 1986;100:107–20.CrossRef
54.
Mothobi NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis. 2011;24(5):503–8.
55.
Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol. 2010;16(2):101–14.PubMedCrossRef
56.
Robinson-Papp J, Elliott KJ, Simpson DM. HIV-related neurocognitive impairment in the HAART era. Curr HIV/AIDS Rep. 2009;6(3):146–52.PubMedCrossRef
57.
Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16.PubMedCrossRef
58.
Giunta B, Ehrhart J, Obregon DF, Lam L, Le L, Jin JJ, et al. Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. Mol Brain. 2011;4:23.PubMedCrossRef
59.
Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol. 2011;11:148.PubMedCrossRef
60.
Dévieux J, Malow R, Stein JA, Jennings TE, Lucenko BA, Averhart C, et al. Impulsivity and HIV risk among adjudicated alcohol and other drug-abusing adolescent offenders. AIDS Educ Prevent. 2002;14(Supplement B):24–3.
61.
Martin EM, Sullivan TS, Reed RA, Fletcher TA, Pitrak DL, Weddington W, Harrow M. Auditory working memory in HIV-1 infection. J Int Neuropsychol Soc. 2001;7(1):20–6.PubMedCrossRef
62.
Courtney KE, Arellano R, Barkley-Levenson E, Gálvan A, Poldrack RA, Mackillop J, David Jentsch J, Ray LA. The relationship between measures of impulsivity and alcohol misuse: an integrative structural equation modeling approach. Alcohol Clin Experim Res. 2011. doi:10.​1111/​j.​1530-0277.​2011.​01635.​x.
63.
MacDonald TK, Zanna MP, Fong GT. Why common sense goes out the window: Effects of alcohol on intentions to use condoms. Personal Soc Psychol Bull. 1996;22:763–75.
64.
Carey K, Scott-Sheldon L, Carey M, Cain D, Mlobeli R, Vermaak R, et al. Community norms for HIV risk behaviors among men in a South African township. J Behav Med. 2011;34(1):32–40.PubMedCrossRef
65.
Catania JA, Coates TJ, Stall R. Changes in condom use among homosexual men in San Francisco. Health Psychol. 1991;10:190–9.PubMedCrossRef
66.
Sobo EJ. Finance, romance, social support, and condoms: use among impoverished inner-city women. Hum Organ. 1995;54:115–28.
67.
Cohen S, Wills TA. Stress, social support and the buffering hypothesis. Psychol Bull. 1985;98:310–57.PubMedCrossRef
68.
Malow RM, Gustman S, Ziskind D, McMahon R, Lawence J. Evaluating HIV prevention interventions among drug abusers: validity issues. J HIV/AIDS Prevent Educ Adolesc Child. 1998;2:21–40.CrossRef
69.
Schroder K, Carey MP, Vanable P. Methodological challenges in research on sexual risk behavior: I accuracy of self-reports. Ann Behav Med. 2003;26:104–23.PubMedCrossRef
70.
Huy NV, Dunne MP, Debattista J, Hien NT, An DTM. Association of human immunodeficiency virus (HIV) preventive information, motivation, self-efficacy and depression with sexual risk behaviors among male freelance laborers. J AIDS HIV Res. 2011;3(1):20–9.
71.
Blume A, Davis J, Schmaling K. Neurocognitive dysfunction in dually-diagnosed patients: a potential roadblock to motivating behavior change. J Psychoact Drugs. 1999;31(2):111–5.CrossRef
72.
Morgenstern J, Bates ME. Effects of executive function impairment on change processes and substance use outcomes in 12-step treatment. J Stud Alcohol. 1999;60(6):846–55.PubMed
73.
Blume AW, Marlatt GA. The role of executive cognitive functions in changing substance use: what we know and what we need to know. Ann Behav Med. 2009;37(2):117–25.PubMedCrossRef
74.
Calsyn D, Hatch-Maillette M, Tross S, Doyle S, Crits-Christoph P, Song Y, et al. Motivational and skills training HIV/sexually transmitted infection sexual risk reduction groups for men. J Subst Abuse Treat. 2009;37(2):138–50.PubMedCrossRef
75.
Anand P, Springer S, Copenhaver M, Altice F. Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav. 2010;14(6):1213–26.PubMedCrossRef
Metadata
Title
Neurological Function, Information–Motivation–Behavioral Skills Factors, and Risk Behaviors Among HIV-Positive Alcohol Users
Authors
Robert M. Malow
Jessy G. Dévieux
Judith A. Stein
Rhonda Rosenberg
Brenda G. Lerner
Jennifer Attonito
Karina Villalba
Publication date
01-11-2012
Publisher
Springer US
Published in
AIDS and Behavior / Issue 8/2012
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-012-0246-6

Other articles of this Issue 8/2012

AIDS and Behavior 8/2012 Go to the issue

Original Paper

Predicting Depression in Mothers With and Without HIV: The Role of Social Support and Family Dynamics

Original Paper

Labor Force Participation and Health-Related Quality of Life in HIV-Positive Men Who Have Sex with Men: The Multicenter AIDS Cohort Study

Original Paper

Aging, Prospective Memory, and Health-Related Quality of Life in HIV Infection

Original Paper

Screening Anxiety in the HIV Clinic

Original Paper

Postnatal Depression Symptoms are Associated with Increased Diarrhea Among Infants of HIV-Positive Ghanaian Mothers

Substantive Review

The Impact of DSM-IV Mental Disorders on Adherence to Combination Antiretroviral Therapy Among Adult Persons Living with HIV/AIDS: A Systematic Review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits